Research lab animals use in medical biotech development (Robocentric biotech development plan)
Subscribe: Apple Podcasts | Google Podcasts | Spotify | RSS | More
Animal testing is absolutely necessary for advancing biotech, I’ve concluded. When the right time, right circumstance, and right money come, I will do laboratory animal testing for advancing medical biotech, human longevity biotech, human genetic engineering biotech, human body manufacturing and replacement biotech, human fertility duration lengthening biotech, and other types of biotechnologies. I’ve a multidecadal commitment to advancing biotech for enabling long-lasting human life and youth, longer human fertility duration, and better human health for everyone.
Doing laboratory animal testing in the U.S. requires adhering to the U.S. federal, state, and local regulations. Boston in Massachusettes, and San Franciso in California, in particular, perform the most numbers of animal tests in the U.S., for advancing biomedicine and biotech.
The Animal Welfare Act is the U.S. federal law that regulates testing on certain types of animals.
According to my calculation, maintaining an Animal Welfare Act compliant animal testing facility in the U.S. requires at least a multiple six-figure U.S. dollars annual overhead or biotech research expense, and most likely over one-million U.S. dollars annual biotech research overhead; as such, it is not cheap.
Because my aim is building a variety of biotech businesses at Robocentric, with multiple biotech product lines, I don’t have to have an Animal Welfare Act compliant animal testing facility in the U.S. to launch the first Robocentric biotech products. As such, I’ll first establish and operate an animal testing facility in the U.S. that isn’t applicable to the Animal Welfare Act, a non-Animal Welfare Act applicable animal testing facility in the U.S., which will be much cheaper than operating an Animal Welfare Act compliant animal testing facility in the U.S., and have very low overhead.
Robocentric will get into a variety of biotech businesses—namely research and medical biotech devices development and manufacturing, medicinal biotech, cosmetic biotech, supplement biotech, and industrial and consumer biomatter design and manufacturing biotech.
For a lot of the biotech products that Robocentric will develop and market, an Animal Welfare Act compliant animal testing facility won’t be absolutely required, and a non-Animal Welfare Act applicable animal testing facility will do, although eventually Robocentric will need one or more Animal Welfare Act compliant animal testing facilities—perhaps in Boston, San Francisco, or both and maybe in other locations—for pushing biotech development and commercialization to the uttermost extremes.
Robocentric will do nonhuman animals genetic engineering experiments, documentation, and publication for advancing medical biotech for curing human genetic diseases by replacing disease-causing human genes with healthy human genes.
Robocentric will do fully robotized genetically engineered nonhuman animal care in confinement for the experiments, 3D scanning, and results publication.
Robocentric will write and publish “Robocentric biotech development plan for nonhuman animals genetic engineering experiments, documentation, and publication for advancing medical biotech for curing human genetic diseases by replacing disease-causing human genes with healthy genes”.
Robocentric will do genetic engineering experiments especially on nonhuman primates, for creating improved nonhuman primates with faster reproduction cycles, and for creating human genetic disease cures.
Robocentric will write and publish “Robocentric biotech development protocols and processes for breeding and performing experiments on nonhuman primates for developing medical biotech with regulations to abide by”.
Robocentric will do age acceleration and deceleration, anti-aging, and deaging biotech development experiments on nonhuman primates such as on chimps for medical research including cancer cure research, human longevity biotech development, and nonhuman-animal and human aging control biotech development.
Robocentric biotech research nonhuman animal breeding and nursery facility in the U.S. will have maximum robotization with less than US$250,000 per year upkeep cost, with all animals in triple confinement (three layers of walls and doors), in comfortably large spaces, with robot-only access in animal confinements for cleaning, feeding, and animal wastes removal.
Robocentric will develop and commercialize chimpanzee genetic engineering biotech, growth hormone biotech, and neurotech—for enabling chimpanzee growth accelerator (for enabling reaching sexual maturity in less than a year), and breeding accelerator (for enabling reproducing every year or less), for much faster biomedical research.
Robocentric will build and maintain its biotech research nonhuman animal breeding and nursery facility or facilities in the U.S., starting at the most appropriate time.
Robocentric will do human fertility duration lengthening biotech R&D (especially for women), which will require nonhuman animal testing, on both non-primates and primates.
Robocentric will do human blindness and deafness cure research, including medical human genetic engineering biotech research. More than 350 eye diseases are attributed to hereditary factors.
Robocentric will do animal testing because research lab animals will provide valuable biological insights for curing the human body diseases, disabilities, damages, and conditions.
At Robocentric Biotech, we’ll treat our research lab animals with dignity, respect, and humane care.
Robocentric will specify in writing and publish how and why research lab animals are used at Robocentric Biotech research facility—for curing human body diseases and disabilities and damages, for developing human longevity biotech, for developing human fertility duration lengthening biotech, for curing human-food animal diseases, for biotech research data measurement, documentation, and publication.
The types of research lab animals used at Robocentric Biotech research facility will be rodents, farm animals, nonhuman primates including chimps, and more.
For developing and commercializing aging control and human fertility duration lengthening biotechnologies, Robocentric will research creating genetically engineered chimpanzees and bonobos with fast growth and sexual maturity, and shorter reproduction cycle.
I will author and publish “Robocentric biotech development sequence and research lab animals breeding, nurturing, and usage plan”, which will include the following.
First, rodent, human-food animal, and nonhuman primates whole-body microscopic 3D scanning, recording, and publication. Second, rodent, human-food animal, and nonhuman primates whole-body biochemical composition analysis and determination, recording, and publication. Third, rodent, human-food animal, and nonhuman primates cancer cure biotech, neurological diseases cure biotech, infectious diseases cure biotech, anti-aging and deaging biotech, genetic engineering biotech, and neurotech development, result recording and publication.
The Robocentric biotech development lab will have enough space for breeding and nurturing all the lab animals–rodents, human-food animals, nonhuman primates, and many more.
At Robocentric, GE-NHP means Genetically Engineered NonHuman Primate. Robocentric will do GE-NHP biomolecule, cell component, cell, tissue, organ, limb, and whole-body manufacturing and replacement experiments for developing human body manufacturing and replacement biotech.
My view is avoiding live animal testing to the maximum extent possible, especially nonhuman primate testing, opting to use manufactured human and nonhuman biomolecules, cell components, cells, tissues, organs, and limbs instead.
Performing tests on live research-lab animals is something I would love to avoid in developing medical biotech, human longevity biotech, and human fertility duration lengthening biotech, because I prefer to avoid harming animals, but for now I think some degree of live research-lab animal testing will probably have to be done to some extent in developing medical biotech, human longevity biotech, and human fertility duration lengthening biotech. I want to avoid doing experiments on nonhuman primates, so I’ll avoid it to the maximum extent possible.
But I’m aware that some difficult choices will have to be made in performing tests on live research-lab animals, especially nonhuman primates. For example, when developing a human genetic engineering biotech for curing a genetically caused human blindness, blindness cure genetic engineering tests must be performed on nonhuman primates, such as monkeys, chimpanzees, and other apes—before human clinical trials—and the test-subject nonhuman primates will have to euthanized and dissected, and their body parts will have to be photographed, microscoped, spectroscoped, biochemically analyzed, recorded, and published for advancing bioscience and biotechnology.
Sacrificing nonhuman animal lives to protect and save human lives is a difficult choice to make; but I’m aware that it’s a difficult decision that must be made, and a difficult act that must be performed, because that is the only way to develop human disease cures and protect and safeguard human lives. So, when the time comes, I’ll plan, direct, coordinate, fund, and publicly communicate performing tests on live research-lab animals, for developing medical biotech, human longevity biotech, and human fertility duration lengthening biotech.
At Robocentric Biotech, first and foremost, biotech development experiments will be done on the animals excluded from the Animal Welfare Act—namely, “birds (such as turkey and chicken), rats of the genus Rattus, and mice of the genus Mus, bred for use in research, and cold-blooded animals, insects, and invertebrates”.
Biotech development experiments on the species of animals covered by the Animal Welfare Act will be done according to the regulation.
Starting with microscopic 3D biomatter scanning, biomatter biochemical analysis and determination, genetic engineering, biomatter manufacturing and replacement testing, neurotech testing on lab-research birds, rats, mice, cold-blooded animals, insects, and invertebrates—then expanding to the species of animals covered by the Animal Welfare Act according to the regulation.
Robocentric will do research on developing nonhuman-primate artificial wombs, for developing human fertility disease and disability cures, and lengthening human fertility periods.
Robocentric will design and publish triple-walled lab animal enclosures—initially for birds, rats, mice, cold-blooded animals, insects, and invertebrates—with security and survelliance cameras, then eventually for the animals covered by the Animal Welfare Act (AWA) for expanding biotech development experiments with a licensing by and registration with USDA under the AWA or Animal Welfare Act.
Before each lab-animal surgery for biotech development and testing, Robocentric will notify the relevant federal, state, and local government agencies and relevant institutions (such as National Institutes of Health) in writing.
Robocentric will constantly report to the relevant federal, state, and local government agencies, and related organizations and institutions, when doing live animal testing for biotech development, with citing their laws, their promotions, their policies, and their recommended practices—as a part of Robocentric biotech development and commercialization process constellation.
In doing animal testing for biotech development and commercialization, Robocentric will work with the applicable U.S. federal government agencies (namely, FDA, USDA, and DEA if using controlled substances in animal testing), state government agencies (namely state board of pharmacy and state board of veterinary medical examiners), and local government agencies. Robocentric will also work with relevant institutions and organizations such as National Institutes of Health, and American Veterinary Medical Association (AVMA).
You can invest in my startup company with as little as US$100, for supporting advancing AI, robotics, biotech, and nuclear-fusion powered outer space tech. Visit Robocentric.com/Investors to invest in my startup.
My books on advancing AI, robotics, biotech, and nuclear-fusion powered outer space tech are available at Robocentric.com/Checkout, Amazon, Apple Books, Spotify, Google Play Store, and other online audiobook retailers.
I am Allen Young; I’m an Asian-American man who focuses on advancing AI, robotics, human longevity biotech, and nuclear-fusion powered outer space tech.
